WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 573776
CAS#: 138-39-6 (acetate)
Description: Mafenide acetate is a sulfonamide that inhibits the enzyme carbonic anhydrase and is used as topical anti-infective, especially in burn therapy.
MedKoo Cat#: 573776
Name: Mafenide acetate
CAS#: 138-39-6 (acetate)
Chemical Formula: C7H10N2O2S
Exact Mass: 186.0463
Molecular Weight: 186.229
Elemental Analysis: C, 45.15; H, 5.41; N, 15.04; O, 17.18; S, 17.22
Related CAS #: 138-39-6 (free base) 12001-72-8 (propionate) 138-37-4 (HCl) 138-39-6 (acetate)
Synonym: Ambamide, Benzamsulfonamide, Emilene, Homonal, Homosul, Mafenide, Marprontil, Mesudin, Mesudrin, Septicid
IUPAC/Chemical Name: Benzenesulfonamide, 4-(aminomethyl)-
InChi Key: TYMRLRRVMHJFTF-UHFFFAOYSA-N
InChi Code: 1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)
SMILES Code: c1cc(ccc1CN)S(=O)(=O)N
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | Mafenide is an effective sulfonamide-type antimicrobial agent used for burn wounds. Mafenide shows activity against both Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa, via inhibition of nucleotide synthesis. |
| In vitro activity: | MAF (mafenide) could inhibit pyroptosis in iBMDM and microglia BV2, and decrease the release of inflammatory factors. MAF could inhibit GSDMD cleavage by directly binding to the GSDMD-Asp275 site, while the expression of p30-GSDMD was simultaneously down-regulated and the release of inflammatory factors was decreased. Reference: Eur J Pharm Sci. 2020 Apr 30;147:105303. https://pubmed.ncbi.nlm.nih.gov/32173407/ |
| In vivo activity: | MAF (mafenide) could reduce the levels of inflammatory factors in cerebrospinal fluid and peripheral blood of APP/PS1 mice, and suppress the activation of microglia. Reference: Eur J Pharm Sci. 2020 Apr 30;147:105303. https://pubmed.ncbi.nlm.nih.gov/32173407/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 30.0 | 161.09 | |
| DMSO:PBS (pH 7.2) (1:4) | 0.2 | 1.07 |
The following data is based on the product molecular weight 186.229 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Han C, Yang Y, Yu A, Guo L, Guan Q, Shen H, Jiao Q. Investigation on the mechanism of mafenide in inhibiting pyroptosis and the release of inflammatory factors. Eur J Pharm Sci. 2020 Apr 30;147:105303. doi: 10.1016/j.ejps.2020.105303. Epub 2020 Mar 12. Erratum in: Eur J Pharm Sci. 2022 Mar 1;170:106099. PMID: 32173407. |
| In vitro protocol: | 1. Han C, Yang Y, Yu A, Guo L, Guan Q, Shen H, Jiao Q. Investigation on the mechanism of mafenide in inhibiting pyroptosis and the release of inflammatory factors. Eur J Pharm Sci. 2020 Apr 30;147:105303. doi: 10.1016/j.ejps.2020.105303. Epub 2020 Mar 12. Erratum in: Eur J Pharm Sci. 2022 Mar 1;170:106099. PMID: 32173407. |
| In vivo protocol: | 1. Han C, Yang Y, Yu A, Guo L, Guan Q, Shen H, Jiao Q. Investigation on the mechanism of mafenide in inhibiting pyroptosis and the release of inflammatory factors. Eur J Pharm Sci. 2020 Apr 30;147:105303. doi: 10.1016/j.ejps.2020.105303. Epub 2020 Mar 12. Erratum in: Eur J Pharm Sci. 2022 Mar 1;170:106099. PMID: 32173407. |
1: Kahn SA, Afshari A, Nguyen L, Shinha T, Huff T, Montgomery AC, Stratton C, Summitt B. Hydrofiber Dressing Saturated With Mafenide Acetate Extends the Duration of Antimicrobial Activity. J Burn Care Res. 2017 Jul/Aug;38(4):e704-e707. doi: 10.1097/BCR.0000000000000455. PubMed PMID: 27775984.
2: Afshari A, Nguyen L, Kahn SA, Summitt B. 2.5% Mafenide Acetate: A Cost-Effective Alternative to the 5% Solution for Burn Wounds. J Burn Care Res. 2017 Jan/Feb;38(1):e42-e47. doi: 10.1097/BCR.0000000000000425. PubMed PMID: 27606553.
3: Pickus EJ, Lionelli GT, Charles EW 3rd, Korentager RA. Mafenide acetate allergy presenting as recurrent chondritis. Ann Plast Surg. 2002 Feb;48(2):202-4. PubMed PMID: 11910229.
